Effect of three months’ treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31 793 patients
| Autor: | Peter Bramlage, F Strutz, W D Paar |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Tetrazoles Blood Pressure Observation Type 2 diabetes 030204 cardiovascular system & hematology Diabetic nephropathy 03 medical and health sciences 0302 clinical medicine Hydrochlorothiazide Irbesartan Internal medicine Diabetes mellitus medicine Humans Prospective Studies 030212 general & internal medicine Antihypertensive Agents Aged business.industry Biphenyl Compounds Drug Tolerance General Medicine Middle Aged medicine.disease 3. Good health Pulse pressure Treatment Outcome Blood pressure Endocrinology Diabetes Mellitus Type 2 Hypertension Cardiology Female Microalbuminuria business medicine.drug |
| Zdroj: | Current Medical Research and Opinion. 21:1433-1440 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1185/030079905x61811 |
| Popis: | In hypertensive diabetics the cardiovascular risk is substantially increased. Therefore, an effective reduction of both blood pressure and pulse pressure is of particular importance for these patients. The aim of the prospective observational study in hypertensive type 2 diabetics was to assess the effect of a switch from the previous antihypertensive therapy to the angiotensin-II-receptor antagonist irbesartan (alone or in combination with HCTZ) on the reduction of blood pressure and pulse pressure, the reduction of diabetic nephropathy (microalbuminuria), and tolerability.8714 general practitioners included 31,793 type 2 diabetics aged at least 18 years in an open observational study. After inclusion in to the study the patients received irbesartan 300 mg as monotherapy or in combination with hydrochlorothiazide 12.5 mg (HCTZ). Main outcome measures for efficacy were the reduction of systolic (SBP) and diastolic (DBP) blood pressures, reduction of pulse pressure, and blood pressure responder (reduction in DBPor = 10 mmHg or diastolic90 mmHg), diastolic normalization (DBP90 mmHg) and overall normalization rates (SBP140 mmHg and DBP90 mmHg) after 3 months. Further outcome measures included the reduction of microalbuminuria or proteinuria, and adverse events (AEs) as a measure of tolerability.Thirty-eight per cent of patients received irbesartan 300 mg and 61% irbesartan in combination with HCTZ. Mean systolic blood pressure was reduced by 22.5 mmHg, diastolic blood pressure by 10.7 mmHg (baseline values: 160.2 and 93.2 mmHg). Pulse pressure fell on average by 11.6 mmHg. 83.4% of the patients were responders, with an overall normalization rate of 42.7% (SBP140 mmHg and DBP90 mmHg), respectively 73.8% (DBP90 mmHg). The antihypertensive benefit was achieved irrespective of the previous medication. Mean albuminuria decreased by about 27.7 mg/L. Only 0.3% of patients experienced adverse events.In type 2 diabetics with hypertension and either uncontrolled or no previous antihypertensive therapy a change to treatment with irbesartan or irbesartan/HCTZ for 3 months resulted in a distinct reduction of systolic and diastolic blood pressures, with concomitant effective reductions of pulse pressure and microalbuminuria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|